Cytokinetics | CYTK - Assets


Cytokinetics reported $1.92B in Assets for its fiscal quarter ending in June of 2026.





Assets Change Date
Acadia Pharmaceuticals USD 1.74B 137.67M Jun/2026
Amgen USD 95.64B 3.14B Jun/2026
Arca Biopharma USD 1.14B 634.91M Jun/2026
Bayer EUR 107.29B 659M Jun/2026
Biogen USD 32.09B 2.6B Jun/2026
Brainstorm Cell Therapeutics USD 788K 33K Jun/2026
Bristol-Myers Squibb USD 87.63B 1.16B Jun/2026
Capricor Therapeutics USD 368.74M 42.45M Jun/2026
Cytokinetics USD 1.92B 651.07M Jun/2026
Eisai JPY 1.56T 108.98B Jun/2026
Eli Lilly USD 142.28B 25.71B Jun/2026
Exelixis USD 2.49B 99.36M Jun/2026
Geron USD 519.01M 15.11M Jun/2026
Halozyme Therapeutics USD 2.58B 95.31M Jun/2026
Ionis Pharmaceuticals USD 2.99B 455.5M Jun/2026
Ligand Pharmaceuticals USD 2.19B 653.77M Jun/2026
Merck USD 129.8B 1.12B Jun/2026
Novartis USD 122.03B 3.5B Jun/2026
Pfizer USD 201.13B 6.49B Jun/2026
Regeneron Pharmaceuticals USD 41.73B 861.8M Jun/2026
Roche Holding CHF 98.2B 2.5B Jun/2026
Sanofi EUR 129.06B 1.04B Jun/2026